Marker Therapeutics, Inc. (MRKR)
About Marker Therapeutics, Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $0
- Net income
- -$12.2M
- Total assets
- $19.1M
- Market cap
- $23.7M
- Operating margin
- -363.5%
- Net margin
- -343.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.5M
- Operating expenses
- $16.4M
- Operating income
- -$12.9M
- Income tax
- -$15.2K
- Net income
- -$12.2M
- EPS (basic)
- $-0.79
- EPS (diluted)
- $-0.79
Balance sheet
- Total assets
- $19.1M
- Current assets
- $19.1M
- Total liabilities
- $2.3M
- Current liabilities
- $2.3M
- Shareholders’ equity
- $16.8M
Cash flow
- Operating cash flow
- -$12.0M
- Investing cash flow
- $2.1M
- Financing cash flow
- $9.9M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $23.7M
- EPS (diluted)
- $-0.79
- Shares outstanding
- 19.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 7, 1998
Marker Therapeutics, Inc. (MRKR) Stock Price
- Reported a net loss of $12.2M in FY2021.
- Revenue grew 186% from FY2021 to FY2025.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Marker Therapeutics, Inc..
Write a review
News about Marker Therapeutics, Inc.
News & sentiment via Polygon.io
Marker Therapeutics, Inc.: frequently asked questions
Is Marker Therapeutics, Inc. an American company?
Marker Therapeutics, Inc. is a US-based company headquartered in Houston, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Marker Therapeutics, Inc. headquartered?
Marker Therapeutics, Inc. is headquartered in Houston, Texas, United States.
Is Marker Therapeutics, Inc. publicly traded?
Yes — Marker Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol MRKR on the NASDAQ.
What does Marker Therapeutics, Inc. do?
Marker Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
